Journal of the American Society of Nephrology, Vol 2, 1014-1020, Copyright © 1991 by American Society of Nephrology

REGULAR ARTICLES

The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients

M Rodriguez, AJ Felsenfeld, C Williams, JA Pederson and F Llach
Department of Medicine, Wadsworth Veterans Administration Medical Center, Los Angeles, CA 90073.

Secondary hyperparathyroidism is common in dialysis patients. Intravenous calcitriol has proven to be an effective therapy for the reduction of parathyroid hormone (PTH) levels. However, the effect of i.v. calcitriol on parathyroid function, defined as the sigmoidal PTH- calcium curve developed during hypocalcemia and hypercalcemia, has not been evaluated during the prolonged administration of i.v. calcitriol. Six hemodialysis patients with marked secondary hyperparathyroidism, PTH levels greater than 500 pg/mL (normal, 10 to 65 pg/mL), were treated for 42 wk with 2 micrograms of i.v. calcitriol after each hemodialysis. Parathyroid function was evaluated before and after 10 and 42 wk of calcitriol therapy. Between baseline and 42 wk, the basal PTH level decreased from 890 +/- 107 to 346 +/- 119 pg/mL (P less than 0.02) and the maximally stimulated PTH level decreased from 1293 +/- 188 to 600 +/- 140 pg/mL (P less than 0.01). In addition, calcitriol administration significantly decreased PTH levels throughout the hypocalcemic range of the PTH-calcium curve. Although the slope of the PTH-calcium curve (with maximal PTH as 100%) decreased between baseline and 42 wk (P less than 0.05), the set point of calcium did not change. Two patients with a decrease in both basal and maximally stimulated PTH levels after 10 wk of calcitriol, developed marked hyperphosphatemia between 10 and 42 wk; this resulted in an exacerbation of hyperparathyroidism despite continued calcitriol therapy. In conclusion, prolonged i.v. calcitriol administration is an effective treatment for secondary hyperparathyroidism in hemodialysis patients provided that reasonable control of the serum phosphate is achieved. In addition, the slope of the PTH-calcium curve may be a better indicator of parathyroid cell sensitivity than the set point of calcium.

This article has been cited by other articles:

				C. Valle, M. Rodriguez, R. Santamaria, Y. Almaden, M. E. Rodriguez, S. Canadillas, A. Martin-Malo, and P. Aljama Cinacalcet Reduces the Set Point of the PTH-Calcium Curve J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2430 - 2436. [Abstract] [Full Text] [PDF]

				A. L. M. de Francisco, M. Izquierdo, J. Cunningham, C. Pinera, R. Palomar, G. F. Fresnedo, J. A. Amado, M. G. Unzueta, and M. Arias Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2895 - 2901. [Abstract] [Full Text] [PDF]

				T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF]

				A. Arabi, N. Khoury, L. Zahed, A. Birbari, and G. El-Hajj Fuleihan Regression of Skeletal Manifestations of Hyperparathyroidism with Oral Vitamin D J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2480 - 2483. [Abstract] [Full Text] [PDF]

				M. Rodriguez, E. Nemeth, and D. Martin The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism Am J Physiol Renal Physiol, February 1, 2005; 288(2): F253 - F264. [Abstract] [Full Text] [PDF]

				R. Minutolo, V. Bellizzi, M. Cioffi, C. Iodice, P. Giannattasio, M. Andreucci, V. Terracciano, B. R. Di Iorio, G. Conte, and L. De Nicola Postdialytic Rebound of Serum Phosphorus: Pathogenetic and Clinical Insights J. Am. Soc. Nephrol., April 1, 2002; 13(4): 1046 - 1054. [Abstract] [Full Text] [PDF]

				F. MALBERTI, D. MARCELLI, F. CONTE, A. LIMIDO, D. SPOTTI, and F. LOCATELLI Parathyroidectomy in Patients on Renal Replacement Therapy: An Epidemiologic Study J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1242 - 1248. [Abstract] [Full Text]

				A. Jara, C. Chacon, A. Valdivieso, L. Aris, R. Jalil, and A. J. Felsenfeld Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia Nephrol. Dial. Transplant., May 1, 2001; 16(5): 1009 - 1016. [Abstract] [Full Text] [PDF]

				A. CANALEJO, Y. ALMADÉN, V. TORREGROSA, J. C. GOMEZ-VILLAMANDOS, B. RAMOS, J. M. CAMPISTOL, A. J. FELSENFELD, and M. RODRÍGUEZ The In Vitro Effect of Calcitriol on Parathyroid Cell Proliferation and Apoptosis J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1865 - 1872. [Abstract] [Full Text]

				J.-H. Brossard, R. Lepage, H. Cardinal, L. Roy, L. Rousseau, C. Dorais, and P. D'Amour Influence of Glomerular Filtration Rate on Non-(1-84) Parathyroid Hormone (PTH) Detected by Intact PTH Assays Clin. Chem., May 1, 2000; 46(5): 697 - 703. [Abstract] [Full Text] [PDF]

				M.-H. Lafage-Proust, C. Combe, N. Barthe, and M. Aparicio Bone Mass and Dynamic Parathyroid Function According to Bone Histology in Nondialyzed Uremic Patients after Long-Term Protein and Phosphorus Restriction J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 512 - 519. [Abstract] [Full Text]

				H. Cardinal, J.-H. Brossard, L. Roy, R. Lepage, L. Rousseau, and P. D’Amour The Set Point of Parathyroid Hormone Stimulation by Calcium Is Normal in Progressive Renal Failure J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3839 - 3844. [Abstract] [Full Text]

				R. Lepage, L. Roy, J.-H. Brossard, L. Rousseau, C. Dorais, C. Lazure, and P. D'Amour A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples Clin. Chem., April 1, 1998; 44(4): 805 - 809. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673